Equip your AI agent with medical & clinical writing expertise

Give any AI agent production-grade medical and scientific writing capability. Built by a CMPP-certified PhD with 10+ years in pharma, this skill turns a general-purpose agent into a domain specialist that drafts to AMA style and CONSORT/STROBE standards — output that survives peer review and MLR, not generic "fluff." Ideal for developers building agents for life-sciences, medical-affairs, or regulatory clients.

What it does

This skill transforms an AI agent into a professional medical writing partner. It supports the entire publication lifecycle, including:

• Journal Submissions: Draft IMRaD sections, structured abstracts, and cover letters.
• Congress Deliverables: Create ASCO/ASH-compliant abstracts, poster narratives, and oral scripts.
• Strategic Planning: Conduct gap analyses, journal selection, and publication planning.
• QC & Compliance: Execute AMA-style edits, MLR promotional checks, and statistical reporting audits according to CONSORT/STROBE.

Why use this skill?

General AI often lacks the nuance needed for medical communications, frequently producing "fluff" or promotional language that fails MLR review. This toolkit enforces data-anchored, non-promotional tone and ensures precise reporting of effect sizes (95% CI) and p-values. It includes the ADAPT framework (Audience, Document, Accuracy, Purpose, Tone) to ensure every output is fit for its specific regulatory or academic context while maintaining strict data safety protocols.

See it in action: MLR compliance check

Prompt:
"Use the promotional language check tool to review this manuscript sentence for MLR compliance: Drug X is a breakthrough therapy that dramatically outperforms all competitors and offers unmatched, superior efficacy for every patient."

Output:

This sentence contains several elements that would likely be flagged during an MLR (Medical-Legal-Regulatory) review due to promotional bias and the lack of qualifying data.

Here is a breakdown of the compliance concerns and suggested revisions:

Compliance Review

• "Breakthrough therapy": This is a specific regulatory designation by the FDA. Using it as a marketing term rather than a factual statement regarding regulatory status is misleading.
• "Dramatically outperforms all competitors": This is a direct comparative claim. Unless you have robust, statistically significant head-to-head data against all competitors, this is non-compliant and potentially disparaging.
• "Unmatched, superior efficacy": "Unmatched" is a superlative that is rarely, if ever, substantiated by clinical data. "Superior" requires specific, pre-specified statistical evidence from a comparative trial.
• "For every patient": This is an absolute claim. Clinical data typically demonstrates efficacy in specific patient populations; claiming "every patient" ignores potential non-responders and safety profiles, making it highly non-compliant.

Suggested Compliant Alternatives

Option 1 (Focus on specific data): "In clinical trials, Drug X demonstrated statistically significant improvements in [Primary Endpoint] compared to [Specific Control/Comparator] in patients with [Indication]."

Option 2 (Focus on clinical profile, if data is limited): "Drug X offers a new treatment option for patients with [Indication], providing meaningful clinical benefits as observed in [Study Name/Reference]."

Recommendation: Remove all superlatives ("unmatched," "dramatically") and absolute claims ("every patient"). Replace comparative language with precise references to the specific study data and the patient population for which the drug is indicated.